newsfilter
← Latest News
GlobeNewswire·

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),